Intravesical Heparin: Interstitial Cystitis (Painful Bladder Syndrome)

Generali, Joyce A.; Cada, Dennis J.

doi:10.1310/hpj4810-822

Cited by 8 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…146,148 Heparin has also been shown to improve symptoms of IC/BPS between 56 and 94% and has a benign side effect profile, similar to placebo. [157][158][159] Although not described in the AUA guidelines, several other intravesical treatments for the management of IC/BPS pain exist. Bacillus Calmette-Guerin (BCG) is believed to work through modulation of an exaggerated immune response and has adverse event profiles comparable to placebo.…”

Section: Treatmentmentioning

confidence: 99%

Interstitial Cystitis/Bladder Pain Syndrome

Marcu

Campian

2018

Semin Reprod Med

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome is an uncommon but potentially devastating pelvic pain disorder affecting both women and men. This condition is often confusable and comorbid with other pelvic pain disorders. Although our understanding of the underlying pathophysiology is growing, the exact longitudinal course by which peripheral and central aberrations involving the bladder mucosa, peripheral inflammation, and central dysregulation of bladder sensitivity create painful bladder symptoms remains an area in need of further study. Only a limited number of drugs have been approved for treatment by the Food and Drug Administration, and overall durable efficacy of the many treatments reviewed in recent American Urological Association guidelines remains suboptimal, making awareness, early diagnosis, and use of effective treatments early in the disease course, where neural changes may still be reversible, imperative.

show abstract

Section: Treatmentmentioning

confidence: 99%

Interstitial Cystitis/Bladder Pain Syndrome

Marcu

Campian

2018

Semin Reprod Med

View full text Add to dashboard Cite

show abstract

“…Reported side effects of a combined instillation affects approximately 30% to 50% of patients and include headache, dizziness, light headedness and bladder or urethral pain. The side effects have been noted at a similar frequency when compared with placebo groups [16]. With doses of 10,000 units of heparin, no increases in activated partial thromboplastin time or prothrombin time were observed [13,14] when the medication was administered three times a week.…”

Section: The Sensory Nerve Systemmentioning

confidence: 65%

The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although these new drugs have the potential to reduce the need for oral heparin, heparins provide a combination of mechanisms that contribute to antithrombotic activity and are unlikely to be replaced by these new anticoagulant drugs. 16 As well, heparins continue to be investigated for use in thrombotic conditions such as large artery occlusive disease 17 or as an adjunct to cancer therapy 4 and for the treatment of other chronic conditions such as interstitial cystitis, 18 asthma, 19 inflammatory bowel disease, 20 and control of angiogenesis, 21 that have little to do with specific anti-Xa or antithrombin activity. Heparins have shown efficacy in many additional conditions including allergic rhinitis, 22 arthritis, 23 transplant rejection, 24 and hypertension.…”

Section: Discussionmentioning

confidence: 99%

Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered

Hiebert

2016

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Low-molecular-weight heparins (LMWHs) endure as important drugs for thromboprophylaxis. Although clinical use relies on the subcutaneous (SC) route, our previous studies show that single-dose orally administered LMWHs have antithrombotic activity. Since thromboprophylaxis requires long-term treatment, we examined antithrombotic effects of subacute oral LMWHs in a rat venous thrombosis model and compared results to SC or single-dose oral administration. We measured LMWH in endothelium and plasma, weight change and complete blood counts (CBC). Oral LMWH tinzaparin (3 × 0.1 mg/kg/12 or 24 hours) or reviparin (3 × 0.025 mg/kg/24 hours) significantly decreased thrombosis compared to saline. In the subacute study (60 × 0.1 mg/kg/12 hours), oral or SC tinzaparin significantly reduced thrombosis compared to saline but not to single or 3 × 0.1 mg/kg/12 hours oral tinzaparin. Antithrombotic effects were similar between oral and SC administration. LMWH was found on endothelium following oral but not SC administration. Endothelial concentrations were significantly correlated with incidence of stable thrombi ( P = 0.021 and 0.04 for aortic and vena cava endothelium respectively, χ test) and total thrombi ( P = 0.003 for vena cava endothelium). Anti-Xa activity was significantly greater for oral or SC LMWH than saline and significantly greater for SC versus oral LMWH. Values for CBCs were within normal ranges (mean ± 2 SD). There was no evidence of bleeding. Weight gain was similar between groups. In conclusion, subacute oral and SC LMWH have similar antithrombotic effects. Antithrombotic activity with oral administration is correlated with endothelial LMWH concentrations but not with plasma anticoagulant activity.

show abstract

Intravesical Heparin: Interstitial Cystitis (Painful Bladder Syndrome)

Cited by 8 publications

References 5 publications

Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis/Bladder Pain Syndrome

The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?

Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered

Contact Info

Product

Resources

About